Emerging technologies, especially those that offer dramatically different levels of control over nature, have certain features in common. In her lecture, Prof. Charo discussed how the science often moves rapidly and unpredictably. Methodologies for risk identification and assessment may not yet be developed, applications across many different product areas are in development simultaneously, and legal authorities designed for an earlier age may be a poor fit when it comes to defining, reviewing, and monitoring the use of these technologies in products ranging from eye shadow to food wrapping to chemotherapy agents. This presentation described some challenges and approaches in the design of a regulatory response that are as nimble and nuanced as the science beyond the products it oversees.
University of Wisconsin and US Food & Drug Administration
Theater, Coffman Memorial Union
The Deinard Memorial Lecture on Law & Medicine is co-sponsored by the University of Minnesota's Joint Degree Program in Law, Health & the Life Sciences and the Center for Bioethics.